Rapid Point of Care Detection of HPV-Associated Malignancies
HPV 相关恶性肿瘤的快速护理点检测
基本信息
- 批准号:10246794
- 负责人:
- 金额:$ 82.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-05-12 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acetic AcidsAnogenital cancerAntibodiesAntigensAreaBiochemistryBiological AssayBiological MarkersBloodBlood specimenCancer CenterCancer DetectionCaringCervicalCervical Cancer ScreeningCervical dysplasiaCervix UteriCessation of lifeClinicalCountryDNADetectionDevelopmentDevicesDiagnosisDiagnosticDiseaseElectrical EngineeringEmerging TechnologiesEngineeringEnzyme-Linked Immunosorbent AssayEuropeFingersFundingHigh grade dysplasiaHuman Papilloma Virus VaccineHuman Papilloma Virus-Related Malignant NeoplasmHuman PapillomavirusHuman papilloma virus infectionHuman papillomavirus 16Immune responseImmunoassayImmunoglobulin GIndiaIndividualInstitutesLogisticsMalignant NeoplasmsMalignant neoplasm of cervix uteriMeasuresMedicalMicroarray AnalysisMicrofluidicsOpticsOutputPap smearPatientsPerformancePhasePilot ProjectsPredictive ValueProtein ArrayProtein MicrochipsProteinsProteomePublicationsQuality ControlReagentResourcesRiskSMART healthSamplingScienceScreening for cancerSensitivity and SpecificitySerologySerology testSerumTechnologyTestingTrainingTriageUnderserved PopulationUnited States National Institutes of HealthValidationViralVisualWomanWorkantibody detectionantigen detectionbiobankbiomarker developmentbiomarker panelbiomarker performancecancer biomarkersconnected healthcostcost effectivedesigndetection assaydetection limitexperienceglobal healthhuman diseaselateral flow assaylow and middle-income countriesmalignant oropharynx neoplasmmortalitymultiplex assaypoint of carepoint-of-care detectionportabilityprogramsprospectiveprototyperesponsescreeningstandard of care
项目摘要
Project Summary. Despite the development of effective human papillomavirus (HPV) vaccines, it has been
estimated that there will be over 200,000 new cases and over 100,000 deaths due to cervical cancer by 2020
in India, which has 25% of the global burden of cases. Cervical cancer screening by Pap smears and HPV
DNA testing has become standard of care in the US and Europe, but has been too expensive and logistically
challenging in low and middle income countries (LMICs). A simple, point-of-care (POC) biomarker panel for
high-grade dysplasia and cervical cancer could provide a cost-effective means for triage of cervical disease in
these countries. HPV infection induces systemic humoral immune responses with IgG antibodies to HPV-
derived proteins. We have previously identified antibodies to a panel of five HPV antigens that detect up to
88% of patients with HPV+ oropharyngeal cancer, but less than 4% of healthy controls. Using an expanded
panel of 16 HPV antigens, we have detected at least one HPV antibody in the sera of 45% of CIN II/III cervical
dysplasia. These results support the development of a rapid, quantitative, and multiplexed assay for the
detection of HPV-related cervical disease. We leverage our protein microarray technology with advances in
fluorescent technologies to enable a fluorescent, programmable, multiplexed ELISA (serologic) assay for HPV-
specific IgG antibodies in a compact and disposable configuration with high analytic sensitivity and rapid,
quantitative output. Our preliminary work in this area has demonstrated detection of IgG antibodies to HPV
antigens with lower limits of detection in the 10pg/mL range, which is a 100-fold improvement over existing
colorimetric approaches. Under our proposed effort, we aim to develop and demonstrate a prototype
multiplexed fluorescent programmable point-of-care assay with high analytical sensitivity for the simultaneous
detection of 16 individual HPV-specific IgG serologic biomarkers from a single finger stick-sized patient blood
sample which can be manufactured for a total reagent cost of less than $1/patient sample. We will leverage our
expertise in immunoassay development with expertise in microfluidics, electrical engineering, optics, biomarker
analytical and clinical validation to target the device and assays for the LMIC clinical setting. We will also
provide a clinical platform and biorepository to rapidly evaluate emerging technologies for cervical screening.
This proposal will adapt the engineering and biochemistry for the development of robust POC devices for
detection of HPV serology specifically for low and middle-income countries. We will transfer and evaluate this
technology, screening 13,000 patients in India, with a team of collaborators in the All India Institute of Medical
Sciences (AIIMS) in New Delhi, India.
项目总结。尽管有效的人乳头瘤病毒(HPV)疫苗的发展,它一直
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karen Sue Anderson其他文献
Karen Sue Anderson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karen Sue Anderson', 18)}}的其他基金
Southwest EDRN Clinical Validation Center for Head and Neck Cancer
西南头颈癌EDRN临床验证中心
- 批准号:
10706931 - 财政年份:2023
- 资助金额:
$ 82.34万 - 项目类别:
High-throughput immunoproteomics for cancer biomarker discovery
用于癌症生物标志物发现的高通量免疫蛋白质组学
- 批准号:
10688268 - 财政年份:2022
- 资助金额:
$ 82.34万 - 项目类别:
Rapid Point of Care Detection of HPV-Associated Malignancies
HPV 相关恶性肿瘤的快速护理点检测
- 批准号:
10006505 - 财政年份:2017
- 资助金额:
$ 82.34万 - 项目类别:
Rapid Point of Care Detection of HPV-Associated Malignancies
HPV 相关恶性肿瘤的快速护理点检测
- 批准号:
9221542 - 财政年份:2017
- 资助金额:
$ 82.34万 - 项目类别:
Rapid Point of Care Detection of HPV-Associated Malignancies
HPV 相关恶性肿瘤的快速护理点检测
- 批准号:
9933545 - 财政年份:2017
- 资助金额:
$ 82.34万 - 项目类别:
Rapid Point of Care Detection of HPV-Associated Malignancies
HPV 相关恶性肿瘤的快速护理点检测
- 批准号:
10471927 - 财政年份:2017
- 资助金额:
$ 82.34万 - 项目类别:
Novel approaches to study immune responses to post translational modifications for cancer detection
研究癌症检测翻译后修饰免疫反应的新方法
- 批准号:
10463894 - 财政年份:2016
- 资助金额:
$ 82.34万 - 项目类别:
Novel approaches to study immune responses to post translational modifications for cancer detection
研究癌症检测翻译后修饰免疫反应的新方法
- 批准号:
9355593 - 财政年份:2016
- 资助金额:
$ 82.34万 - 项目类别:
相似海外基金
ANOGENITAL CANCER--EPIDEMIOLOGY/BIOCHEMISTRY/IMMUNOLOGY
肛门生殖器癌--流行病学/生物化学/免疫学
- 批准号:
6580339 - 财政年份:2002
- 资助金额:
$ 82.34万 - 项目类别:
ANOGENITAL CANCER--EPIDEMIOLOGY, BIOCHEMISTRY, AND IMMUNOLOGY
肛门生殖器癌——流行病学、生物化学和免疫学
- 批准号:
6340760 - 财政年份:1999
- 资助金额:
$ 82.34万 - 项目类别:
ANOGENITAL CANCER--EPIDEMIOLOGY, BIOCHEMISTRY, AND IMMUNOLOGY
肛门生殖器癌——流行病学、生物化学和免疫学
- 批准号:
6203112 - 财政年份:1999
- 资助金额:
$ 82.34万 - 项目类别:
HUMAN PAPILLOMAVIRUS AND PROGNOSIS OF FEMALE ANOGENITAL CANCER
人乳头瘤病毒与女性肛门生殖器癌的预后
- 批准号:
6340761 - 财政年份:1999
- 资助金额:
$ 82.34万 - 项目类别:
HUMAN PAPILLOMAVIRUS AND PROGNOSIS OF FEMALE ANOGENITAL CANCER
人乳头瘤病毒与女性肛门生殖器癌的预后
- 批准号:
6203113 - 财政年份:1999
- 资助金额:
$ 82.34万 - 项目类别:
ANOGENITAL CANCER--EPIDEMIOLOGY, BIOCHEMISTRY, AND IMMUNOLOGY
肛门生殖器癌——流行病学、生物化学和免疫学
- 批准号:
6102322 - 财政年份:1998
- 资助金额:
$ 82.34万 - 项目类别:
HUMAN PAPILLOMAVIRUS AND PROGNOSIS OF FEMALE ANOGENITAL CANCER
人乳头瘤病毒与女性肛门生殖器癌的预后
- 批准号:
6102323 - 财政年份:1998
- 资助金额:
$ 82.34万 - 项目类别:
HUMAN PAPILLOMAVIRUS AND PROGNOSIS OF FEMALE ANOGENITAL CANCER
人乳头瘤病毒与女性肛门生殖器癌的预后
- 批准号:
6236844 - 财政年份:1997
- 资助金额:
$ 82.34万 - 项目类别:
ANOGENITAL CANCER--EPIDEMIOLOGY, BIOCHEMISTRY, AND IMMUNOLOGY
肛门生殖器癌——流行病学、生物化学和免疫学
- 批准号:
6236843 - 财政年份:1997
- 资助金额:
$ 82.34万 - 项目类别:
ANOGENITAL CANCER--EPIDEMIOLOGY/BIOCHEMISTRY/IMMUNOLOGY
肛门生殖器癌--流行病学/生物化学/免疫学
- 批准号:
6442269 - 财政年份:1987
- 资助金额:
$ 82.34万 - 项目类别:














{{item.name}}会员




